Additional file 3 of PMCA inhibition reverses drug resistance in clinically refractory cancer patient-derived models

Additional file 3: Figure S1. Scheme of pharmacophore candidates. Figure S2. Selected cells survived by induction of PMCA under glucose deprivation induced metabolic stress conditions. Immunoblot analysis for PMCA expression (A and B top), cell viability assay (A and B middle) and intracellular calcium measurements (A and B bottom) after PMCA knockdown in selected cells. A: S-231, B: S-MCF-7. Figure S3. Immunoblot analysis of HNF4α and NFκB nuclear translocation. A: P-231 and S-231, B: P-MCF-7 and S-MCF-7. Figure S4. Representative images of dissected tumors at completion of treatment schedule with selected cells. A: S-231, B: S-MCF-7. Figure S5. Representative images of dissected tumors at completion of treatment schedule with patient-derived cancer cells. A: YUMC-C1, B: YUMC-C2, C: YUMC-P1. Figure S6. Changes in relative tumor volumes at different doses of caloxin and candidate 13. A and B: S-231, C and D: S-MCF-7. The dose of 2DG was fixed. Data are presented as mean ± standard error of mean. *P